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LETTERS TO THE EDITORRegarding “Screening for abdominal aortic aneurysm:
A consensus statement”
With interest I read the consensus statement formulated by
Kent et al on screening for abdominal aortic aneurysms (J Vasc
Surg 2004;39:267-9). Among other issues, it is stated that when
evaluating the cost and effectiveness of screening programs, the
accuracy of the screening test and prevalence of the disease must be
considered. Randomized controlled trials (RCTs) are considered
the gold standard for evaluating the effectiveness of interventions
and guiding decisions on patient management. The authors state
that the benefit of screening programs has been demonstrated in 6
prospective randomised studies. However, to this date only 3
RCTs have been published,1-3 while the final results of a fourth still
have to be awaited.4 In these 4 studies a 21% to 68% decrease in
aneurysm-related deaths was observed. In 2 of the studies, this mor-
tality reduction reached statistical significance.2,3 One of these studies
was biased because only in-hospital mortality was recorded.2
The prevalence of aortic dilatation 3 cm in the male general
population is 4% to 8%. However, only a small portion of these men
will eventually qualify for an operation because the diameter of the
aorta has reached 5.5 cm and the risk of rupture exceeds 1% per year.
Although the relative risk reduction (RRR) in aneurysm-related mor-
tality seems remarkable, the absolute risk reduction (ARR) ranges
between only .05% and .21% due to the low prevalence of men with
large aneurysms. This implies that 476 to 2000 men need to be
screened to prevent 1 aneurysm-related death (NNS).
When regarding these data, it is a question of who will benefit
from a screening program for all men aged 60 to 85 years and women
aged 60 to 85 years with cardiovascular risk factors, because for
women it has been shown in a subgroup analysis that a screening
program does not reduce aneurysm-related mortality at all due to the
even lower prevalence of abdominal aortic aneurysms (Table). 6
Mark Koelemay, MD, PhD
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Dr Koelemay, in his letter to the Journal of Vascular Surgery,
questions the findings of the recently published consensus state-
ment advocating screening for abdominal aortic aneurysms (AAA).
We recognize that screening for aneurysms has been a controversial
topic; in fact, this controversy was the impetus for the organization
of the panel that generated this document. Re-evaluation seemed
warranted in light of the significant amount of new data that have
become available over the past several years regarding screening for
aneurysms.
When considering screening for any disease, multiple factors
must be evaluated. Broadly, these include the invasiveness and cost
of the screening test, the prevalence of disease, the associated
mortality and morbidity if the disease is left undetected, and the
risk and cost of treatment. It is difficult to isolate any 1 of these
individual variables since each contributes to the overall cost and
efficacy of screening. Koelemay’s primary concern is with one of
these variables, the prevalence of disease. He calculates that to
prevent 1 aneurysm related death it may be necessary to screen over
500 patients. In terms of cost-effectiveness, however, a 5-minute
inexpensive test applied to even 2000 patients may be worthwhile
if one death can be prevented.1 It is worth noting that a similar
analysis revealed that 1200 to 2500 patients need to be screened
with mammography to prevent 1 breast cancer–related death.2,3
Certainly, screening for aneurysms compares favorably with
other well-accepted screening tests. We and others have conducted
cost-effective analyses in which all of the important variables are
considered. We found a cost-effectiveness ratio associated for
screening of $11,215, a number that compares quite favorably
with screening for breast cancer ($16,000) as well as coronary
artery bypass for left main disease ($9,500).1 Koelemay points out
that it is difficult to show a dramatic effect for AAA screening on
the overall death rate. This is because ruptured AAAs accounts for
a relatively low proportion of the overall mortality of any popula-
tion. Deaths from other causes, such as myocardial infarction and
cancer, statistically overwhelm those from AAA (or for that matter
prostate or breast cancer). However, randomized trials have re-
peatedly shown a dramatic effect of screening on death in patients
who have aneurysms. Koelemay also raises concerns about the
efficacy of screening for AAAs in women. We agree there are very
few data that allow the definition of a subpopulation of women that
should be screened. The available information does suggest that
women with multiple comorbidities have a reasonably high preva-
lence of aneurysmal disease. Thus, we have recommended screen-
ing of this patient cohort, albeit this area deserves further evalua-
tion.
In conclusion, we feel there are strong supportive data that
favor screening for AAAs in selected populations. The incidence of
ruptured AAAs in the United States has not changed over the past
20 years; up to 30,000 people die of ruptured AAAs each year.4 We
are hopeful that screening programs for aneurysms will have an
Author Men’s age RRR ARR NNS
Vardulaki1 65-80 21% .20% 500
Lindholt2 65-73 68% .21% 476
Ashton3 65-74 42% .14% 714
Lawrence-Brown4 65-83 28%* .05%* 2000*
*Data derived from Lederle FA, 2003.5
